CN104470909B - 用于治疗脊髓性肌萎缩的化合物 - Google Patents
用于治疗脊髓性肌萎缩的化合物 Download PDFInfo
- Publication number
- CN104470909B CN104470909B CN201380027139.9A CN201380027139A CN104470909B CN 104470909 B CN104470909 B CN 104470909B CN 201380027139 A CN201380027139 A CN 201380027139A CN 104470909 B CN104470909 B CN 104470909B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- formula
- amino
- compound
- chromen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC*C(*=NC(*)C1O*(C)=N2)=C1C2=O Chemical compound CC*C(*=NC(*)C1O*(C)=N2)=C1C2=O 0.000 description 21
- HQCCNFFIOWYINW-UHFFFAOYSA-N CC(c1cc(Br)ccc1O)=O Chemical compound CC(c1cc(Br)ccc1O)=O HQCCNFFIOWYINW-UHFFFAOYSA-N 0.000 description 1
- GXHUTBJQBJVVDR-SNAWJCMRSA-N Cc1c[s]c(/C=C/C(c2cc(Br)ccc2O)=O)n1 Chemical compound Cc1c[s]c(/C=C/C(c2cc(Br)ccc2O)=O)n1 GXHUTBJQBJVVDR-SNAWJCMRSA-N 0.000 description 1
- GFLQOSHYLVBJQK-UHFFFAOYSA-N Cc1c[s]c(C(Oc(c2c3)ccc3Br)=CC2=O)n1 Chemical compound Cc1c[s]c(C(Oc(c2c3)ccc3Br)=CC2=O)n1 GFLQOSHYLVBJQK-UHFFFAOYSA-N 0.000 description 1
- ZIFYBYOLTSKDHB-UHFFFAOYSA-N Cc1c[s]c(C(Oc(cc2)c3cc2N2CCNCC2)=CC3=O)n1 Chemical compound Cc1c[s]c(C(Oc(cc2)c3cc2N2CCNCC2)=CC3=O)n1 ZIFYBYOLTSKDHB-UHFFFAOYSA-N 0.000 description 1
- NYMCQLLAIMUVSY-UHFFFAOYSA-N Cc1c[s]c(C=O)n1 Chemical compound Cc1c[s]c(C=O)n1 NYMCQLLAIMUVSY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614932P | 2012-03-23 | 2012-03-23 | |
| US61/614,932 | 2012-03-23 | ||
| PCT/US2013/031232 WO2013142236A1 (en) | 2012-03-23 | 2013-03-14 | Compounds for treating spinal muscular atrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104470909A CN104470909A (zh) | 2015-03-25 |
| CN104470909B true CN104470909B (zh) | 2018-04-24 |
Family
ID=49223223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380027139.9A Active CN104470909B (zh) | 2012-03-23 | 2013-03-14 | 用于治疗脊髓性肌萎缩的化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9914722B2 (enExample) |
| EP (1) | EP2828247B1 (enExample) |
| JP (1) | JP6219921B2 (enExample) |
| KR (1) | KR102109992B1 (enExample) |
| CN (1) | CN104470909B (enExample) |
| BR (1) | BR112014023483B1 (enExample) |
| CA (1) | CA2868026C (enExample) |
| EA (1) | EA028382B1 (enExample) |
| MX (1) | MX358514B (enExample) |
| WO (1) | WO2013142236A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013101974A1 (en) | 2011-12-30 | 2013-07-04 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| BR112014018027B1 (pt) | 2012-01-26 | 2020-10-27 | Ptc Therapeutics, Inc | composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn |
| EP2812004B1 (en) | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| BR112014021531B1 (pt) | 2012-03-01 | 2022-10-04 | Ptc Therapeutics, Inc. | Composto, composição farmacêutica e usos dos mesmos |
| EA201500699A1 (ru) * | 2012-12-24 | 2015-12-30 | Рамот Эт Тель-Авив Юниверсити Лтд. | Агенты для лечения генетических заболеваний, возникающих в результате нонсенс-мутаций, и способы идентификации этих агентов |
| MX372669B (es) | 2013-08-19 | 2020-04-23 | Hoffmann La Roche | Un compuesto que modifica el empalme del gen de foxm1 para usarse en la profilaxis o tratamiento de cáncer. |
| US10195202B2 (en) | 2013-12-19 | 2019-02-05 | Ptc Therapeutics, Inc. | Methods for modulating the amount of RNA transcripts |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| TN2017000508A1 (en) | 2015-06-26 | 2019-04-12 | Takeda Pharmaceuticals Co | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| CN108697709A (zh) | 2015-12-10 | 2018-10-23 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
| AU2017363369A1 (en) | 2016-11-28 | 2019-05-30 | Ptc Therapeutics, Inc | Methods for modulating RNA splicing |
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| US11608501B2 (en) | 2017-06-14 | 2023-03-21 | Ptc Therapeutics, Inc. | Methods for modifying RNA splicing |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| WO2019005993A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| WO2019168170A1 (ja) * | 2018-03-02 | 2019-09-06 | 国立大学法人 長崎大学 | クロモン誘導体及びアミロイド関連疾患診断用組成物 |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| EP3816160A4 (en) | 2018-06-27 | 2022-03-16 | Reborna Biosciences, Inc. | PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY |
| CN114007613A (zh) | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| JP7603595B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| KR102823820B1 (ko) * | 2022-09-01 | 2025-06-23 | 단국대학교 천안캠퍼스 산학협력단 | 퓨로크로멘온계 화합물을 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학 조성물 |
| WO2024249554A1 (en) * | 2023-05-30 | 2024-12-05 | The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health | Multitarget small molecule inhibitors and uses thereof |
| AU2024286618A1 (en) * | 2023-06-09 | 2025-10-30 | F. Hoffmann-La Roche Ag | Inducible gene expression system |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH479607A (de) | 1967-02-27 | 1969-10-15 | Geigy Ag J R | Verfahren zur Herstellung von Areno-oxazinonverbindungen |
| US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| GB1296469A (enExample) * | 1970-02-05 | 1972-11-15 | ||
| US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5726182A (en) | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
| US5278174A (en) | 1990-06-04 | 1994-01-11 | Scios Nova, Inc. | Sigma binding site agents |
| WO1993023398A1 (en) | 1992-05-13 | 1993-11-25 | E.I. Du Pont De Nemours And Company | Substituted pyrido[1,2-a]pyrimidinone derivatives as fungicides |
| ATE169924T1 (de) * | 1993-05-18 | 1998-09-15 | Takeda Chemical Industries Ltd | Benzopyran-derivate und ihre verwendung |
| US5597922A (en) | 1994-07-29 | 1997-01-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Glycine receptor antagonist pharmacophore |
| WO2000017197A1 (en) | 1998-09-21 | 2000-03-30 | Biochem Pharma Inc. | Quinolizinones as integrin inhibitors |
| DE60128655T2 (de) | 2000-01-24 | 2008-02-07 | Astrazeneca Ab | Durch einen morpholinrest substituierte therapeutische verbindungen |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| AU2003237492A1 (en) | 2002-06-10 | 2003-12-22 | Acadia Pharmaceuticals Inc. | Urotensin ii receptor modulators |
| CA2495661C (en) | 2002-08-16 | 2011-06-14 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
| CN101260104A (zh) * | 2002-08-16 | 2008-09-10 | 阿斯利康(瑞典)有限公司 | 抑制磷酸肌醇3-激酶β |
| US20040105849A1 (en) * | 2002-11-25 | 2004-06-03 | Kaloidis Antonia C. | Treatment for SMA disease |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| AU2004249730A1 (en) | 2003-06-20 | 2004-12-29 | Novartis Vaccines And Diagnostics, Inc. | Pyridino(1,2-A)pyrimidin-4-one compounds as anticancer agents |
| AU2004289303A1 (en) | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
| DE602005002562T2 (de) | 2004-05-04 | 2008-01-31 | Warner-Lambert Company Llc | Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel |
| CA2584485C (en) * | 2004-10-20 | 2013-12-31 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| US7399767B2 (en) | 2005-01-21 | 2008-07-15 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| US20090123563A1 (en) | 2005-02-07 | 2009-05-14 | Novo Nordisk A/S | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand |
| CN101365446B (zh) * | 2005-07-29 | 2013-05-22 | 雷斯弗洛吉克斯公司 | 预防和治疗复杂疾病的药物组合物及其经由可植入医药装置的递送 |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| ES2539828T3 (es) | 2007-09-14 | 2015-07-06 | Naturewise Biotech & Medicals Corporation | Compuestos para la inhibición de la histona de acetilasa |
| US8008344B2 (en) | 2007-09-14 | 2011-08-30 | NatureWise Biotech and Medicals Corporation | Compounds for the inhibition of histone deacetylase |
| ES2388196T3 (es) | 2008-03-06 | 2012-10-10 | Rottapharm S.P.A. | Derivados de 2-aril- y 2-heteroaril-4H-1-benzopiran-4-ona-6-amidino para el tratamiento de artritis, cáncer y dolor relacionado |
| WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| WO2010019243A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc. | Methods for treating viral infections |
| WO2010048273A2 (en) * | 2008-10-21 | 2010-04-29 | President And Fellows Of Harvard College | Methods and compounds for treatment of neurodegenerative disorders |
| CN101851220A (zh) * | 2009-04-03 | 2010-10-06 | 彦臣生技药品股份有限公司 | 异戊二烯类黄酮化合物及其用途 |
| JP5806672B2 (ja) | 2009-10-30 | 2015-11-10 | ドメイン・セラピューティクス | 新規オキシム誘導体及び代謝型グルタミン酸受容体のアロステリック調節因子としての利用 |
| HRP20171537T1 (hr) | 2009-11-05 | 2017-12-15 | Rhizen Pharmaceuticals S.A. | Novi modulatori benzopiran kinaze |
| US8754220B2 (en) | 2009-11-20 | 2014-06-17 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide M1 receptor positive allosteric modulators |
| US20130012506A1 (en) | 2010-01-13 | 2013-01-10 | Zaesung No | Anti-infective pyrido (1,2-a) pyrimidines |
| WO2011130515A1 (en) * | 2010-04-14 | 2011-10-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production |
| KR101992311B1 (ko) | 2011-05-04 | 2019-09-27 | 리젠 파마슈티컬스 소시에떼 아노님 | 단백질 키나아제의 조절제로서 신규한 화합물 |
| WO2013101974A1 (en) | 2011-12-30 | 2013-07-04 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| BR112014018027B1 (pt) | 2012-01-26 | 2020-10-27 | Ptc Therapeutics, Inc | composto, composição farmacêutica e usos dos mesmos e métodos para aumentar a inclusão de éxon 7 de ame2 em rnam que é transcrito a partir do gene ame2 e para aumentar a quantidade de proteína smn |
| EP2812004B1 (en) | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| BR112014021531B1 (pt) | 2012-03-01 | 2022-10-04 | Ptc Therapeutics, Inc. | Composto, composição farmacêutica e usos dos mesmos |
-
2013
- 2013-03-14 CN CN201380027139.9A patent/CN104470909B/zh active Active
- 2013-03-14 KR KR1020147029409A patent/KR102109992B1/ko active Active
- 2013-03-14 JP JP2015503291A patent/JP6219921B2/ja active Active
- 2013-03-14 MX MX2014011233A patent/MX358514B/es active IP Right Grant
- 2013-03-14 CA CA2868026A patent/CA2868026C/en active Active
- 2013-03-14 WO PCT/US2013/031232 patent/WO2013142236A1/en not_active Ceased
- 2013-03-14 EA EA201491766A patent/EA028382B1/ru not_active IP Right Cessation
- 2013-03-14 EP EP13763520.7A patent/EP2828247B1/en active Active
- 2013-03-14 US US14/386,524 patent/US9914722B2/en active Active
- 2013-03-14 BR BR112014023483-3A patent/BR112014023483B1/pt active IP Right Grant
Non-Patent Citations (3)
| Title |
|---|
| (Aminoalkoxy)chromones. Selective σ Receptor Ligands;Ronald H.Erickson等;《J. Med. Chem.》;19921231;第35卷;第1529页表I * |
| Bacteriostatic activity of 6- and 7-amino and N-substitued aminoflavones;M.VIJAYA LAKSHMI等;《Current Science》;19721231;第41卷(第8期);第681页左栏表II第5项 * |
| Synthesis of 6-aminomethyl derivates of benzopyran-4-one with dual biological properties:Anti-inflammatory-analgesic and antimicrobial;S.M.Hasan等;《European Journal of Medicinal Chemistry》;20091231;第44卷;第4897页方案1、摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2868026A1 (en) | 2013-09-26 |
| US20150080383A1 (en) | 2015-03-19 |
| CA2868026C (en) | 2021-02-16 |
| JP2015517988A (ja) | 2015-06-25 |
| EP2828247B1 (en) | 2019-01-16 |
| EA028382B1 (ru) | 2017-11-30 |
| BR112014023483B1 (pt) | 2022-05-10 |
| MX2014011233A (es) | 2014-11-25 |
| BR112014023483A2 (enExample) | 2017-06-20 |
| EA201491766A1 (ru) | 2015-03-31 |
| EP2828247A1 (en) | 2015-01-28 |
| US9914722B2 (en) | 2018-03-13 |
| KR102109992B1 (ko) | 2020-05-13 |
| JP6219921B2 (ja) | 2017-10-25 |
| CN104470909A (zh) | 2015-03-25 |
| HK1202527A1 (en) | 2015-10-02 |
| EP2828247A4 (en) | 2015-12-16 |
| KR20140135840A (ko) | 2014-11-26 |
| MX358514B (es) | 2018-08-24 |
| WO2013142236A1 (en) | 2013-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104470909B (zh) | 用于治疗脊髓性肌萎缩的化合物 | |
| EP2809322B1 (en) | Compounds for treating spinal muscular atrophy | |
| EP2819519B1 (en) | Compounds for treating spinal muscular atrophy | |
| JP6193881B2 (ja) | 脊髄性筋萎縮症を治療するための化合物 | |
| HK1202069B (en) | Compounds for treating spinal muscular atrophy | |
| HK1200056B (en) | Compounds for treating spinal muscular atrophy | |
| HK1202527B (en) | 4h-chromen-4-one derivatives for treating spinal muscular atrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |